Association between functional EGF+61 polymorphism and glioma risk

Clinical Cancer Research

Volumn 13, Issue 9, 2007, Pages 2621-2626

  Costa, Bruno Marques ^a   Ferreira, Paulo ^d   Costa, Sandra ^a   Canedo, Paulo ^d   Oliveira, Pedro ^b   Silva, Ana ^c   Pardal, Fernando ^c   Suriano, Gianpaolo ^d   Machado, José Carlos ^d   Lopes, José Manuel ^d   Reis, Rui Manuel ^a  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c HOSPITAL DE BRAGA   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; LUCIFERASE;

ADULT; AGED; ALLELE; ARTICLE; CANCER CLASSIFICATION; CANCER RISK; CANCER SURVIVAL; CASE CONTROL STUDY; CONTROLLED STUDY; CRANIOTOMY; FEMALE; GENOTYPE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN POLYMORPHISM; REPORTER GENE;

ALLELES; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; EPIDERMAL GROWTH FACTOR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLIOMA; HUMANS; MALE; POLYMORPHISM, GENETIC; RISK;

EID: 34249104304     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2606     Document Type: Article

References (42)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP. Years of life lost (YLL) from cancer is an important measure of population burden - and should be considered when allocating research funds. Br J Cancer 2005;92:241-5.
3. Kleihues P, Cavanee WK. Pathology and genetics of tumours of the nervous system. 2nd ed. Lyon: IARC Press; 2000.
4. Butowski NA, Sneed PK, Chang SM. Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol 2006;24:1273-80.
5. Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 1998;88:1-10.
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
7. Xian CJ, Zhou XF. EGF family of growth factors: essential roles and functional redundancy in the nerve system. Front Biosci 2004;9:85-92.
8. Zhu Y, Parada LF. The molecular and genetic basis of neurological tumours. Nat Rev Cancer 2002;2:616-26.
9. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
10. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor α, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 1991;51:2164-72.
11. Hunter KW, Crawford NP. Germ line polymorphism in metastatic progression. Cancer Res 2006;66: 1251-4.
12. Loktionov A. Common gene polymorphisms, cancer progression and prognosis. Cancer Lett 2004; 208:1-33.
13. Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 2003;3:912-20.
14. Nagasubramanian R, Innocenti F, Ratain MJ. Pharmacogenetics in cancer treatment. Annu Rev Med 2003;54:437-52. Epub 2001 Dec 3.
15. Zhang W, Gordon M, Press OA, et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenomics 2006;16:475-83.
16. Shahbazi M, Pravica V, Nasreen N, et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002;359:397-401.
17. McCarron SL, Bateman AC, Theaker JM, Howell WM. EGF +61 gene polymorphism and susceptibility to and prognostic markers in cutaneous malignant melanoma. Int J Cancer 2003;107:673-5.
18. Amend KL, Elder JT, Tomsho LP, et al. EGF gene polymorphism and the risk of incident primary melanoma. Cancer Res 2004;64:2668-72.
19. Randerson-Moor JA, Gaut R, Turner F, et al. The relationship between the epidermal growth factor (EGF) 5′UTR variant A61G and melanoma/nevus susceptibility. J Invest Dermatol 2004;123:755-9.
20. Howell WM. Epidermal growth factor gene polymorphism and development of cutaneous melanoma. J Invest Dermatol 2004;123:xx-xxi.
21. James MR, Hayward NK, Dumenil T, Montgomery GW, Martin NG, Duffy DL. Epidermal growth factor gene (EGF) polymorphism and risk of melanocytic neoplasia. J Invest Dermatol 2004;123:760-2.
22. Okamoto I, Roka F, Krogler J, et al. The EGF A61G polymorphism is associated with disease-free period and survival in malignant melanoma. J Invest Dermatol 2006;126:2242-6.
23. Bhowmick DA, Zhuang Z, Wait SD, Weil RJ. A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res 2004;64:1220-3.
24. Basto D, Trovisco V, Lopes JM, et al. Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol (Berl) 2005;109:207-10.
25. Mullenbach R, Lagoda PJ, Welter C. An efficient salt-chloroform extraction of DNA from blood and tissues. Trends Genet 1989;5:391.
26. Wacholder S, Chanock S, Garcia-Closas M, El GL, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96: 434-42.
27. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol (Berl) 2005;109:93-108.
28. Ron E, Modan B, Boice JD, Jr., et al. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med 1988;319:1033-9.
29. Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991;325:1330-6.
30. Relling MV, Rubnitz JE, Rivera GK, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999;354:34-9.
31. Walter AW, Hancock ML, Pui CH, et al. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital. J Clin Oncol 1998;16:3761-7.
32. Wrensch M, Fisher JL, Schwartzbaum JA, Bondy M, Berger M, Aldape KD. The molecular epidemiology of gliomas in adults. Neurosurg Focus 2005;19:E5.
33. Wiencke JK, Aldape K, McMillan A, et al. Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase. Cancer Epidemiol Biomarkers Prev 2005;14:1774-83.
34. Wang LE, Bondy ML, Shen H, et al. Polymorphisms of DNA repair genes and risk of glioma. Cancer Res 2004;64:5560-3.
35. Caggana M, Kilgallen J, Conroy JM, et al. Associations between ERCC2 polymorphisms and gliomas. Cancer Epidemiol Biomarkers Prev 2001;10: 355-60.
36. Elexpuru-Camiruaga J, Buxton N, Kandula V, et al. Susceptibility to astrocytoma and meningioma: influence of allelism at glutathione S-transferase (GSTT1 and GSTM1) and cytochrome P-450 (CYP2D6) loci. Cancer Res 1995;55:4237-9.
37. Ezer R, Alonso M, Pereira E, et al. Identification of glutathione S-transferase (GST) polymorphisms in brain tumors and association with susceptibility to pediatric astrocytomas. J Neurooncol 2002;59:123-34.
38. Wrensch M, Kelsey KT, Liu M, et al. Glutathione-S-transferase variants and adult glioma. Cancer Epidemiol Biomarkers Prev 2004;13:461-7.
39. Louis DN, Holland EC, Cairncross JG. Glioma classification: a molecular reappraisal. Am J Pathol 2001; 159:779-86.
40. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479-89.
41. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33: 369-85.
42. Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz CR. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 2006;32:74-89.